Abstract: FR-PO923
Hyperuricemia and Polygenic Risk Score for CKD: Evaluating Its Impact Beyond Genetic Predisposition for CKD
Session Information
- CKD Epidemiology, Risk Factors, Prevention - II
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Kim, Yaerim, Keimyung University School of Medicine, Daegu, Korea (the Republic of)
- Paek, Jin hyuk, Keimyung University School of Medicine, Daegu, Korea (the Republic of)
- Jin, Kyubok, Keimyung University School of Medicine, Daegu, Korea (the Republic of)
- Han, Seungyeup, Keimyung University School of Medicine, Daegu, Korea (the Republic of)
- Lee, Jung Pyo, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Dongjak-gu, Seoul, Korea (the Republic of)
- Kim, Dong Ki, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)
- Lim, Chun Soo, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Dongjak-gu, Seoul, Korea (the Republic of)
- Lee, Jeonghwan, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Dongjak-gu, Seoul, Korea (the Republic of)
Background
The bidirectional effect of hyperuricemia on chronic kidney disease (CKD) underscores the importance of hyperuricemia as a risk factor for CKD. We evaluated the effect of hyperuricemia on the presence and development of CKD after considering genetic background by calculating polygenic risk scores (PRSs).
Methods
We employed genome-wide association study summary statistics—excluding the United Kingdom Biobank (UKB) datasets among published CKD Gen Consortium papers—to calculate the PRSs for CKD in white background subjects. To validate PRS performance, we divided the UKB into two datasets to validate and test the data. We used logistic regression analysis to evaluate the association between hyperuricemia and CKD, and performed Cox proportional hazard analysis exclusively for subjects with available follow-up data.
Results
In total, 438,253 clinical data points and 4,307,940 single nucleotide polymorphisms from 459,155 samples were included. We observed a significant positive association between PRS and CKD and the presence and development of CKD. Hyperuricemia significantly increased CKD risk (adjusted odds ratio 1.54, 95% confidence interval 1.49–1.58). The impact of hyperuricemia on CKD was maintained irrespective of PRS range but was more pronounced in subjects with low PRS (1st tertile range). Survival analysis indicates that the presence of hyperuricemia significantly increased the risk of CKD development.
Conclusion
The PRS for CKD thoroughly reflects the risk of CKD development. Hyperuricemia is a significant indicator of CKD risk, even after incorporating the genetic risk score for CKD. Irrespective of genetic risk, patients with a prospective risk of developing CKD require uric acid monitoring and management.